Updated Results of the Selective Bruton Tyrosine kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies
Started June 18, 2021
262
VIDEO: Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies
Started April 15, 2021
235
VIDEO: A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Started April 15, 2021
284
VIDEO: Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial
Started April 15, 2021
568
VIDEO: Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL
Started April 15, 2021
308
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients with Relapsed/Refractory Indolent Lymphoma
Started March 9, 2021
1118
Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL
Started December 7, 2020
469
Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial
Started December 7, 2020
484
A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Started December 7, 2020
257
Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies
Started December 5, 2020
279
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
Started December 2, 2020
477
A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Started November 5, 2020
429